EP0446713B1 - Système de séparation du sang - Google Patents

Système de séparation du sang Download PDF

Info

Publication number
EP0446713B1
EP0446713B1 EP91102992A EP91102992A EP0446713B1 EP 0446713 B1 EP0446713 B1 EP 0446713B1 EP 91102992 A EP91102992 A EP 91102992A EP 91102992 A EP91102992 A EP 91102992A EP 0446713 B1 EP0446713 B1 EP 0446713B1
Authority
EP
European Patent Office
Prior art keywords
bag
blood
outlet
tubing
satellite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP91102992A
Other languages
German (de)
English (en)
Other versions
EP0446713A3 (en
EP0446713A2 (fr
Inventor
Raleigh A. Carmen
Willie J. Lewis
Eva Sajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Pall Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of EP0446713A2 publication Critical patent/EP0446713A2/fr
Publication of EP0446713A3 publication Critical patent/EP0446713A3/en
Application granted granted Critical
Publication of EP0446713B1 publication Critical patent/EP0446713B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components

Definitions

  • This disclosure is concerned generally with collection and separation systems for whole blood and specifically with a blood component separation system that can be partially automated.
  • Whole blood is commonly separated into its major components of less dense plasma and more dense red blood cells (RBCs) by first drawing the whole blood into a plastic bag known as a donor or primary bag. The bag's contents are then centrifuged under controlled conditions to result in a lower, more dense portion of packed RBCs and an upper less dense plasma portion, which may be rich in platelets (platelet rich plasma or PRP).
  • RBCs red blood cells
  • the donor bag is typically connected by plastic tubing to one or more satellite bags into which separated blood components (e.g. the PRP) may be expressed by external manipulation for further processing or use.
  • separated blood components e.g. the PRP
  • the classical method of preparing platelet transfusion products from whole blood collections consists of initial centrifugation of whole blood in a plastic blood bag at relatively low centrifugal force to separate most of the PRP from the red cells.
  • the PRP is commonly expressed into an attached satellite blood bag. This is followed by centrifugation of the PRP in the satellite bag at relatively high centrifugal force to form a lower sediment of platelets and an upper platelet poor plasma (PRP).
  • the sedimented platelets are in the form of a pellet or "button" which is resuspended in a small volume (50-60 mL) of donor plasma to give the platelet concentrate.
  • the buffy coat plus either a small volume of plasma or a synthetic medium is then centrifuged at low centrifugal force to separate platelet concentrate (upper layer) from residual red cells and leukocytes.
  • platelet concentrate upper layer
  • the Amsterdam method while apparently giving respectable platelet yields, was cumbersome and labor-intensive.
  • the buffy coat transfer step required the operator to massage the bag to prevent hang-up of the "sticky" buffy coat layer. These manipulations might influence platelet function and release of granulocyte enzymes. There was also no way to control the volume of buffy coat removed.
  • U.S. Patent 3,911,918 to Turner discloses a blood bag having an hour glass shape. That bag has a top portion for plasma, a bottom portion for RBCs and a middle portion for platelets and white blood cells.
  • the hour glass shape is said to help position clamping or sealing devices at the juncture of the separated components after whole blood in the bag is centrifuged. This system has not been used on any significant commercial scale to date.
  • Our system for separation of blood components comprises a main plastic bag having inlet and at least two outlet ports, all of the outlets being at the top of the bag.
  • One outlet port is in closed communication with or capable of being connected to an empty plasma satellite bag adapted to hold plasma.
  • the other outlet port communicates at one end with a tube extending into and within the bag and close to the bag bottom and at the other end is in closed communication with or capable of being connected to a second bag adapted to hold red blood cells.
  • the second satellite bag contains an RBC preservative solution such as AS-3.
  • whole blood is drawn into the main bag via the inlet port and then centrifuged to form an upper, less dense plasma portion, an intermediate buffy coat portion (containing platelets) and a lower, more dense packed red blood cell portion.
  • Pressure is then applied to the bag to express the upper plasma portion through the first outlet into the empty plasma satellite bag via a conventional blood bag connecting tubing.
  • a sensor or photocell adapted to sense a color change as the last of the plasma (or first of the buffy coat) passes through the tubing.
  • the color change at the start or the top of the buffy coat portion can activate the sensor at which time the sensor activates a clamp (or valve) which closes the tubing connected to the first outlet port.
  • the senor When the tubing of the first outlet is thus closed, the sensor simultaneously opens or activates a clamp (valve) in a tubing connecting the main bag with the second satellite bag adapted to hold red blood cells. This allows passage of the RBCs (from the tube extending into the bottom of the bag) to pass into the second satellite bag until a pre-determined volume of buffy coat remains in the main or primary bag. This leaves only buffy coat and platelets in the original bag.
  • the Figure is a plan view of a preferred blood bag separation system of this disclosure.
  • Our system for the separation of blood components and particularly for the preparation of platelet concentrate from buffy coat comprises a bag having sensor activated clamps or valves associated with each of the outlet ports as part of the bag.
  • the outlet port for the RBCs communicates with a tubular extension extending to the bottom of the bag interior.
  • the tube is flexible to minimize breaking or bending during centrifuging. This also helps avoid bag puncture and breaking of the solvent bond where the tube connects to the outlet port.
  • the tube is preferably transparent and extends to within about 1.27 cm (1/2 inch) of the interior bottom of the bag.
  • it is made from conventional blood bag PVC tubing and has a beveled tip to avoid blockage and assure fluid (RBC) flow even if the end of the tube actually touches or presses against the bag bottom.
  • a preferred system is a "triple" blood bag consisting of a primary or donor bag and two satellite bags pre-connected to the primary bag by conventional blood bag tubing.
  • the primary bag is made using conventional techniques but is modified in that the blood collection bag has a RBC outlet tube extending from a top outlet port to the bottom of the bag as shown in Figure 1. All bags and connecting tubings are made from conventional blood bag plastics (e.g. PVC and the like) and are essentially transparent.
  • the triple unit After collection of whole blood into bag 3, the triple unit is centrifuged at relatively high centrifugal force to form upper plasma component 9, intermediate buffy coat component 13, and lower red cell component 11.
  • the bag 3 is then placed in a simple pressure-separator device (blood bag expresser) consisting of a moving spring-loaded expresser plate and a fixed plate.
  • the separation system includes two on-off tubing clamps, 19 and 31, one on tubing 17 and one on tubing 27, activated by a sensor such as a photocell. Plasma passes through tube 17 while the tubing that conveys red cells passes through tube 27.
  • a simple clamp 19 on tubing 17 is open and a simple clamp 31 on tubing 27 is closed.
  • Plasma is expressed into bag 21 by pressure on bag 3 until red cells (in the buffy coat) are first detected in tubing 17 by the photocell sensor 16, at which time clamp 19 on tubing 17 closes in response to an electrical signal on wire line 25 from sensor 16 and the clamp 31 on tubing 27 opens in response to a signal on similar line 25.
  • Red cells are then expressed from the beveled bottom 7a of tube extension 7 through the top of bag 3 into second satellite bag 35 containing a conventional red cell preservation solution such as AS-3 or the like (not shown).
  • the expression continues until only a volume of about 50mL (the buffy coat 13) remains in bag 3. This volume may be set, if desired, by a simple stop between the expresser plate and the backplate against which the bag 3 is pressed in an otherwise conventional blood bag expresser.
  • a preferred method of processing buffy coat to platelet concentrate after centrifugation is as follows. After the plasma and RBC expressions and detaching the plasma bag 21 and the red cell bag 35, the buffy coat 13 is held in the primary bag 3 overnight, preferably at room temperature with agitation. A number of bags containing buffy coat, preferably 6, are pooled together using a Sterile Connection Device (e.g. such as that shown in U.S. Patent 4,507,119) into a bag containing a platelet additive solution. A platelet pooling bag such as that shown in U.S. 4,857,190 to S. Wada and B. Kuhleman can be used.
  • a Sterile Connection Device e.g. such as that shown in U.S. Patent 4,507,119
  • a platelet pooling bag such as that shown in U.S. 4,857,190 to S. Wada and B. Kuhleman can be used.
  • the pool of platelets is centrifuged at low centrifugal force to form an upper platelet concentrate (PC) layer and a lower layer of undesirable red cells and leukocytes.
  • the PC may also be expressed through a leukocyte filter (e.g. as shown in U.S. 4,810,378 to R.A. Carmen et al) into a 1000 mL storage bag made of a plastic with high 02 and CO2 transmission rates for storage (e.g. as shown in U.S. 4,280,497 to Warner et al.).
  • the triple bag system of this invention was used to prepare components including buffy coat platelet concentrate from 6 individual units of blood.
  • the buffy coats were processed individually rather than as a pool.
  • Whole blood was collected into a primary blood bag and the bag was centrifuged at 3000Xg for 9 minutes.
  • the plasma upper layer was expressed into an attached empty satellite bag followed by expression of red cell lower layer from the bottom and out of the top of the primary bag into an attached bag containing AS-3 RBC preservation solution.
  • Platelet counts were performed on all fractions using either an electronic cell counter (plasma and platelet concentrate) or a manual method. Data are summarized in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (11)

  1. Système de fractionnement du sang entier en ses composants, comprenant une poche à sang (3) présentant au moins deux lumières de sortie (17) et (27) à sa partie supérieure, à savoir une première lumière (27) et une seconde lumière (17), la première lumière (27) communiquant avec un élément tubulaire (7) pénétrant et s'engageant à l'intérieur de la poche (3) et se terminant à une distance juste au-dessus du fond de la poche.
  2. Système suivant la revendication 1, dans lequel l'élément tubulaire s'étend jusqu'à environ 1,27 cm (1/2 in) du fond de l'intérieur de la poche.
  3. Système suivant la revendication 2, dans lequel l'élément tubulaire est flexible et se termine en biseau.
  4. Système suivant la revendication 1, dans lequel la seconde lumière de sortie communique avec une première poche à sang (21) satellite par une tubulure.
  5. Système suivant la revendication 4, dans lequel la tubulure communiquant avec une pince extérieure (19) contient un capteur (16) qui arrête le passage du fluide dans la tubulure.
  6. Système suivant la revendication 1, dans lequel la première lumière de sortie communique avec une seconde poche à sang (35) satellite par une tubulure.
  7. Système suivant la revendication 6, dans lequel la tubulure communiquant avec une pince extérieure (19) comprend un capteur (16) arrêtant le passage du fluide dans la tubulaire.
  8. Système suivant la revendication 5, dans lequel le capteur, après détection et arrêt du passage du fluide dans la tubulure, communique avec et ouvre une vanne extérieure (19) sur la tubulure reliant la seconde lumière de sortie à la poche à sang de manière que du fluide puisse être transféré de la poche à la seconde poche satellite par la lumière de sortie.
  9. Procédé pour fractionner du sang en ses composants, comprenant les étapes qui consistent :
    (a) à introduire du sang entier dans une poche à sang (3) présentant au moins deux lumières de sortie (17) et (27) à la partie supérieure de la poche (3), l'une des lumières de sortie communiquant avec un élément tubulaire (7) débouchant et s'engageant dans la poche et se terminant à environ 1,27 cm (1/2 in) du fond intérieur de la poche ;
    (b) à centrifuger la poche à sang (3) avec une force centrifuge relativement grande pour former une fraction supérieure (9) de plasma, une fraction intermédiaire (13) formée d'une couche leucocytaire et une fraction inférieure formée d'hématies ;
    (c) à exercer une pression sur la poche pour en exprimer le plasma par une lumière de sortie ; et
    (d) à exercer une pression sur la poche pour en exprimer la protéine des globules rouges par l'élément tubulaire.
  10. Procédé suivant la revendication 9, dans lequel chaque lumière de sortie est en communication obturée par l'intermédiaire de la tubulure avec une poche satellite (21, 35).
  11. Procédé suivant la revendication 9, dans lequel les tubulures reliant les poches satellites aux lumières de sortie comprennent un capteur (16) et une pince (19, 31) qui coopèrent d'une manière prédéterminée pour ouvrir et fermer le passage au fluide par les lumières de sortie.
EP91102992A 1990-03-13 1991-02-28 Système de séparation du sang Expired - Lifetime EP0446713B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US493024 1990-03-13
US07/493,024 US5102407A (en) 1990-03-13 1990-03-13 Blood separation system

Publications (3)

Publication Number Publication Date
EP0446713A2 EP0446713A2 (fr) 1991-09-18
EP0446713A3 EP0446713A3 (en) 1992-01-29
EP0446713B1 true EP0446713B1 (fr) 1994-08-10

Family

ID=23958590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91102992A Expired - Lifetime EP0446713B1 (fr) 1990-03-13 1991-02-28 Système de séparation du sang

Country Status (7)

Country Link
US (1) US5102407A (fr)
EP (1) EP0446713B1 (fr)
AT (1) ATE109655T1 (fr)
CA (1) CA2037813A1 (fr)
DE (1) DE69103297T2 (fr)
DK (1) DK0446713T3 (fr)
ES (1) ES2056508T3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616254A (en) 1990-11-06 1997-04-01 Pall Corporation System and method for processing biological fluid

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780333B1 (en) 1987-01-30 2004-08-24 Baxter International Inc. Centrifugation pheresis method
US5104526A (en) * 1987-01-30 1992-04-14 Baxter International Inc. Centrifugation system having an interface detection system
US5258126A (en) * 1989-09-12 1993-11-02 Pall Corporation Method for obtaining platelets
US5360545A (en) * 1989-09-12 1994-11-01 Pall Corporation Filter for obtaining platelets
DK119490D0 (da) * 1990-05-14 1990-05-14 Unes As Apparat til fremstilling af et koncentrat af koagulationsfaktorer, saasom fibrinogen, fra en blodportion
US5154716A (en) * 1990-11-06 1992-10-13 Miles Inc. Bottom blood bag separation system
US5935092A (en) 1990-12-20 1999-08-10 Baxter International Inc. Systems and methods for removing free and entrained contaminants in plasma
DK167517B1 (da) * 1991-11-11 1993-11-15 Squibb & Sons Inc Beholder til optagelse og adskillelse af en vaeske, fortrinsvis blodplasma, i dennes bestanddele
CA2072378C (fr) * 1991-11-21 2000-12-26 Vlado Ivan Matkovich Methode d'assemblage de plusieurs receptables contenant un fluide biologique
US5785869A (en) * 1992-02-10 1998-07-28 Baxter International Inc. Method for creating a leukocyte rich sample from a mixed population of blood cells
US5686238A (en) * 1992-02-10 1997-11-11 Baxter International Inc. Method and device for testing blood units for viral contamination
SE9200857D0 (sv) * 1992-03-19 1992-03-19 Omega Teknik Hb Saett och anordning foer uttag av blodkomponenter
CA2083075A1 (fr) * 1992-06-10 1993-12-11 Vlado I. Matkovich Systeme pour le traitement du materiau de la zone de transition
GR930100237A (el) * 1992-06-10 1994-02-28 Pall Corp Σύστημα δια την επεξεργασίαν υλικού ζώνης μεταπτώσεως.
BE1006620A5 (fr) * 1992-07-13 1994-11-03 Pall Corp Systeme automatise et methode de traitement de fluides biologiques.
GB9218581D0 (en) * 1992-09-02 1992-10-14 Pall Corp Removal of unwanted fluids from processed blood products
US5316681A (en) * 1992-11-06 1994-05-31 Baxter International Inc. Method of filtering body fluid using a rinse chamber bag
ZA948564B (en) * 1993-11-19 1995-07-26 Bristol Myers Squibb Co Liquid separation apparatus and method
US5437598A (en) * 1994-01-21 1995-08-01 Cobe Laboratories, Inc. Automation of plasma sequestration
WO1995031266A1 (fr) * 1994-05-11 1995-11-23 Baxter International Inc. Systeme de collecte de sang
US5547108A (en) * 1994-08-02 1996-08-20 Pall Corporation Expressor
PL320512A1 (en) * 1994-12-02 1997-10-13 Bristol Myers Squibb Co System for feeding a reagent into a centrifuge
US5733446A (en) * 1994-12-02 1998-03-31 Bristol-Myers Squibb Company Centrifuge with annular filter
DE69535816D1 (de) * 1994-12-02 2008-10-02 Vivolution As Methode und vorrichtung zum abtrennen von fibrinmonomer aus blutplasma
US5733545A (en) * 1995-03-03 1998-03-31 Quantic Biomedical Partners Platelet glue wound sealant
JPH11508813A (ja) 1995-06-06 1999-08-03 クウォンティック バイオメディカル パートナーズ 血漿を濃縮するための装置及び方法
US5656154A (en) * 1995-06-07 1997-08-12 Organ, Inc. Method and apparatus for separating a fluid into components and for washing a material
US5865785A (en) * 1996-02-23 1999-02-02 Baxter International Inc. Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes
US6190855B1 (en) 1996-10-28 2001-02-20 Baxter International Inc. Systems and methods for removing viral agents from blood
US6168718B1 (en) 1996-11-08 2001-01-02 Pall Corporation Method for purifying blood plasma and apparatus suitable therefor
US6695803B1 (en) 1998-10-16 2004-02-24 Mission Medical, Inc. Blood processing system
US6716187B1 (en) * 1999-07-08 2004-04-06 Implant Innovations, Inc. Platelet concentration syringe kit
ATE337806T1 (de) 1999-07-08 2006-09-15 Implant Innovations Inc Spritzenkit für die konzentration von thrombozyten und verfahren
CA2373689A1 (fr) * 1999-07-29 2001-02-08 Thomas W. Coneys Support de tube de prelevement destine a un systeme de prelevement de sang
US6387086B2 (en) * 1999-07-29 2002-05-14 Baxter International Inc. Blood processing set including an integrated blood sampling system
US7824343B2 (en) 1999-07-29 2010-11-02 Fenwal, Inc. Method and apparatus for blood sampling
US7435231B2 (en) 1999-07-29 2008-10-14 Fenwal, Inc. Biological sample device receiver
WO2002089725A2 (fr) * 2001-05-08 2002-11-14 Nexell Therapeutics Inc. Dispositifs de transfert de fluide et leurs procedes d'utilisation
US7264608B2 (en) * 2001-12-05 2007-09-04 Fenwal, Inc. Manual processing systems and methods for providing blood components conditioned for pathogen inactivation
US6820506B2 (en) * 2002-03-27 2004-11-23 3M Innovative Properties Company Multi-chambered pump-valve device
US7241281B2 (en) * 2002-04-08 2007-07-10 Thermogenesis Corporation Blood component separation method and apparatus
US20050137517A1 (en) * 2003-12-19 2005-06-23 Baxter International Inc. Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation
US7442178B2 (en) * 2005-03-09 2008-10-28 Jacques Chammas Automated system and method for blood components separation and processing
AU2006305989B2 (en) 2005-10-26 2013-10-24 Genesis Technologies Limited Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products
AU2008282232A1 (en) * 2007-08-01 2009-02-05 Terumo Bct Biotechnologies, Llc. Pathogen inactivation of whole blood
JP5695574B2 (ja) 2009-11-10 2015-04-08 テルモ株式会社 血液バッグシステム及び血液処理方法
US9555171B2 (en) 2010-09-30 2017-01-31 Depuy Mitek, Llc Methods and devices for collecting separate components of whole blood
CN103492041B (zh) * 2011-03-28 2017-02-08 新健康科学股份有限公司 用于在红细胞血液处理过程中使用惰性载气和歧管组件去除氧和二氧化碳的方法和系统
CN103191016B (zh) * 2012-01-09 2015-07-29 金卫医疗科技(上海)有限公司 一种血液连续分离时提高血浆提取纯度的分离软袋
CA2893039C (fr) * 2012-11-30 2021-09-28 Toray Industries, Inc. Procede de preparation de solution de plaquettes remplacee par une solution de conservation artificielle
EP3509663B1 (fr) * 2016-09-06 2024-07-03 Fresenius Kabi Deutschland GmbH Procédé automatisé et appareil pour la collecte de leucocytes à partir de sang total
CN110484502A (zh) * 2019-07-27 2019-11-22 王太林 一种活性白细胞收集装置及收集方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2934069A (en) * 1956-10-19 1960-04-26 Baxter Laboratories Inc Plasma aspirating equipment
US3304977A (en) * 1965-01-11 1967-02-21 Velikanje Moore & Countryman Blood container
US4146172A (en) * 1977-10-18 1979-03-27 Baxter Travenol Laboratories, Inc. Centrifugal liquid processing system
SE416378B (sv) * 1979-03-28 1980-12-22 Johansson A S Sett vid separation av blodkomponenter ur helblod jemte blodpassystem for utforandeav settet
US4413771A (en) * 1979-09-10 1983-11-08 E. I. Du Pont De Nemours And Company Method and apparatus for centrifugal separation
SE8206767D0 (sv) * 1982-11-26 1982-11-26 Seroteknik Hb Sett och anordning for satsvis centrifugalseparering av blod
JPS6171064A (ja) * 1984-09-13 1986-04-11 日本赤十字社 血液成分の分離用器具
US4810378A (en) * 1986-04-21 1989-03-07 Miles Laboratories, Inc. Red blood cell filtering system
US4917804A (en) * 1986-10-31 1990-04-17 Baxter International Inc. Method and vessel for separation of cryoglobin
FR2625320B1 (fr) * 1987-12-28 1990-05-18 Rgl Transfusion Sanguine Centr Appareil automatique de separation des composants du sang
US4895275A (en) * 1988-08-30 1990-01-23 Corpak, Inc. Dispensing spike for penetrable pre-filled shape retentive containers
US4997577A (en) * 1989-12-20 1991-03-05 Baxter International Inc. Systems and methods for removing undesired matter from blood cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616254A (en) 1990-11-06 1997-04-01 Pall Corporation System and method for processing biological fluid

Also Published As

Publication number Publication date
US5102407A (en) 1992-04-07
ES2056508T3 (es) 1994-10-01
CA2037813A1 (fr) 1991-09-14
DE69103297D1 (de) 1994-09-15
ATE109655T1 (de) 1994-08-15
DK0446713T3 (da) 1994-09-19
EP0446713A3 (en) 1992-01-29
DE69103297T2 (de) 1994-12-01
EP0446713A2 (fr) 1991-09-18

Similar Documents

Publication Publication Date Title
EP0446713B1 (fr) Système de séparation du sang
US5154716A (en) Bottom blood bag separation system
CA2035929C (fr) Filtration pre-stockage des plaquettes sanguines
US5236716A (en) Platelets concentrate with low white blood cells content
US5300060A (en) Blood bag system for separation and isolation of neocytes and gerocytes
US7452344B2 (en) Platelet concentration syringe kit
EP1202758B1 (fr) Trousse de seringues a concentration de plaquettes et procedure
US4464167A (en) Pheresis apparatus
EP1267990B1 (fr) Systèmes et procédés pour collecter des composants sanguins sans leucocytes, comprenant le plasma exempt ou pratiquement exempt d'espèces sanguines cellulaires
US4416654A (en) Pheresis apparatus
US4772256A (en) Methods and apparatus for autotransfusion of blood
CA1280721C (fr) Sac pour la separation et l'isolement des composantes du sang
AU651646B2 (en) System and method for processing biological fluids
US5104788A (en) Method of preparing neocytes and gerocytes in a closed system
US20180140758A1 (en) Closed disposable multiple sterile blood bag system for fractionating blood with the corresponding method
US8333725B2 (en) Device comprising a container system for a bodily fluid
US5360545A (en) Filter for obtaining platelets
US6428712B1 (en) Gravity driven liquid filtration system and method for filtering biological liquid
US4969882A (en) Bag for separation and isolation of blood components
EP0523180B1 (fr) Sac a sang servant a separer les composants du sang
WO2000007642A1 (fr) Systeme de traitement de fluides biologiques
JP2005000394A (ja) 血液成分分離装置および血液成分の分離・移送方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19920318

17Q First examination report despatched

Effective date: 19930716

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 109655

Country of ref document: AT

Date of ref document: 19940815

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69103297

Country of ref document: DE

Date of ref document: 19940915

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2056508

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
ITF It: translation for a ep patent filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950101

Year of fee payment: 5

EAL Se: european patent in force in sweden

Ref document number: 91102992.4

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3013865

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: MILES INC. TRANSFER- BAYER CORPORATION * BAYER COR

NLS Nl: assignments of ep-patents

Owner name: PALL CORPORATION

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: BAYER CORPORATION

BECA Be: change of holder's address

Free format text: 960918 *PALL CORP.:25 HARBOR PARK DRIVE PORT WASHINGTON NY 11050

BECH Be: change of holder

Free format text: 960918 *PALL CORP.:25 HARBOR PARK DRIVE PORT WASHINGTON NY 11050

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19970212

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970311

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970410

Year of fee payment: 7

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980228

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980302

BERE Be: lapsed

Owner name: PALL CORP.

Effective date: 19980228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990204

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19990209

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19990211

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19990222

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990224

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19990226

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990304

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19991231

Year of fee payment: 10

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000228

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000301

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000901

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001031

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000901

EUG Se: european patent has lapsed

Ref document number: 91102992.4

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20011010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050228